TXG - 10X Genomics Inc Stock Price, Fair Value and News

26.89USD-0.63 (-2.29%)Market Closed

Market Summary

USD26.89-0.63

Market Closed

-2.29%

TXG Stock Price

View Fullscreen

TXG RSI Chart

TXG Valuation

Market Cap

3.2B

Price/Earnings (Trailing)

-12.55

Price/Sales (Trailing)

5.18

EV/EBITDA

-13.33

Price/Free Cashflow

-50.2

TXG Price/Sales (Trailing)

TXG Profitability

Operating Margin

66.15%

EBT Margin

-40.21%

Return on Equity

-34.42%

Return on Assets

-26.43%

Free Cashflow Yield

-1.99%

TXG Fundamentals

TXG Revenue

Revenue (TTM)

618.7M

Rev. Growth (Yr)

17.76%

Rev. Growth (Qtr)

19.74%

TXG Earnings

Earnings (TTM)

-255.1M

Earnings Growth (Yr)

-184.36%

Earnings Growth (Qtr)

47.36%

Breaking Down TXG Revenue

Last 7 days

-7.1%

Last 30 days

-25.8%

Last 90 days

-37.8%

Trailing 12 Months

-47.3%

How does TXG drawdown profile look like?

TXG Financial Health

Current Ratio

4.69

TXG Investor Care

Shares Dilution (1Y)

3.39%

Diluted EPS (TTM)

-2.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	536.2M	568.4M	591.0M	618.7M
2022	499.2M	497.9M	503.7M	516.4M
2021	332.8M	405.7M	459.2M	490.5M
2020	264.2M	251.3M	261.9M	298.8M
2019	172.5M	196.6M	221.2M	245.9M
2018	89.9M	108.7M	127.5M	146.3M
2017	0	0	0	71.1M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of 10X Genomics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 21, 2024	mcanear justin j.	acquired	-	-	53,312	chief financial officer
Mar 21, 2024	saxonov serge	acquired	-	-	88,854	chief executive officer
Mar 21, 2024	hindson benjamin j.	acquired	-	-	71,083	see remarks
Mar 14, 2024	saxonov serge	gifted	-	-	-1,086	chief executive officer
Mar 04, 2024	saxonov serge	sold	-205,021	43.9959	-4,660	chief executive officer
Feb 22, 2024	hindson benjamin j.	sold	-121,098	46.3443	-2,613	see remarks
Feb 22, 2024	mcanear justin j.	sold	-86,432	46.3443	-1,865	chief financial officer
Feb 22, 2024	saxonov serge	sold	-130,737	46.3443	-2,821	chief executive officer
Feb 15, 2024	saxonov serge	sold	-244,332	48.8664	-5,000	chief executive officer
Feb 09, 2024	saxonov serge	sold	-49,530	49.5301	-1,000	chief executive officer

Which funds bought or sold TXG recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	DekaBank Deutsche Girozentrale	unchanged	-	-42,000	74,000	-%
Apr 24, 2024	Spire Wealth Management	sold off	-100	-794	-	-%
Apr 24, 2024	Activest Wealth Management	unchanged	-	-755	1,539	-%
Apr 24, 2024	Assenagon Asset Management S.A.	added	260	1,395,290	2,379,400	0.01%
Apr 23, 2024	FIFTH THIRD BANCORP	added	2,216	200,925	214,747	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-67.74	-818,000	226,000	-%
Apr 23, 2024	Venturi Wealth Management, LLC	reduced	-21.92	-5,839	6,418	-%
Apr 23, 2024	Global Retirement Partners, LLC	reduced	-87.21	-6,830	826	-%
Apr 22, 2024	MetLife Investment Management, LLC	reduced	-1.36	78,684	311,417	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	sold off	-100	-406,829	-	-%

Are Funds Buying or Selling TXG?

Are funds buying TXG calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TXG

No. of Funds

Unveiling 10X Genomics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	8.65%	9,011,332	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 31, 2024	blackrock inc.	5.5%	5,705,051	SC 13G/A
Jan 29, 2024	baillie gifford & co	7.60%	7,919,976	SC 13G/A
Dec 08, 2023	morgan stanley	3.5%	3,630,398	SC 13G/A
Jul 10, 2023	morgan stanley	5.2%	5,139,461	SC 13G/A
Jul 10, 2023	fmr llc	-	0	SC 13G/A
Feb 14, 2023	venrock associates vi, l.p.	4.9%	4,828,247	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	8.81%	8,420,011	SC 13G/A

Recent SEC filings of 10X Genomics Inc

View All Filings

Date Filed	Form Type	Document
Apr 12, 2024	PRE 14A	PRE 14A
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 04, 2024	144	Notice of Insider Sale Intent
Feb 26, 2024	4	Insider Trading
Feb 26, 2024	4	Insider Trading
Feb 26, 2024	4	Insider Trading

Peers (Alternatives to 10X Genomics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	455.4B	371.6B	0.35%	2.29%	20.35	1.23	14.64%	11.24%
CI	103.7B	195.3B	-0.89%	42.87%	19.3	0.53	8.17%	-20.79%
CVS	84.7B	357.8B	-15.14%	-6.85%	10.14	0.24	10.95%	93.52%
HCA	83.0B	65.0B	-4.22%	12.88%	15.84	1.28	7.86%	-7.11%
CNC	40.5B	154.0B	-2.44%	13.57%	14.98	0.26	6.54%	124.79%
DVA	11.6B	12.1B	-1.82%	53.92%	16.84	0.96	4.57%	23.40%
UHS	11.4B	14.3B	-6.87%	15.65%	15.95	0.8	6.59%	6.24%
MID-CAP
CHE	8.7B	2.3B	-10.00%	2.41%	31.85	3.83	6.06%	9.17%
ACHC	6.8B	2.9B	-4.41%	-0.94%	-312.68	2.31	12.20%	-107.93%
AMN	2.1B	3.8B	-9.00%	-34.66%	10.11	0.56	-27.73%	-52.50%
AMEH	2.0B	1.4B	-7.34%	3.16%	33.41	1.46	21.19%	34.42%
SMALL-CAP
ADUS	1.5B	1.1B	-10.65%	-18.57%	23.79	1.4	11.31%	35.83%
BKD	1.3B	3.0B	6.69%	62.95%	-6.87	0.43	6.74%	20.73%
BEAT	51.9M	-	-9.63%	1.03%	-3.54	-	-	-12.94%
AMS	19.7M	21.3M	20.46%	12.23%	37.05	0.93	8.00%	-62.25%

10X Genomics Inc News

Latest updates

10X Genomics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	19.7%	183,979,000	153,644,000	146,819,000	134,285,000	156,232,000	131,072,000	114,609,000	114,496,000	143,530,000	125,297,000	115,842,000	105,821,000	112,218,000	71,817,000	42,905,000	71,905,000	75,289,000	61,207,000	55,819,000	53,578,000	50,554,000
Cost Of Revenue	17.3%	68,197,000	58,115,000	47,207,000	35,895,000	36,827,000	30,377,000	27,704,000	25,478,000	27,598,000	24,518,000	4,915,000	17,060,000	18,897,000	14,411,000	10,052,000	15,108,000	16,582,000	15,480,000	15,006,000	13,965,000	-
Gross Profit	21.2%	115,782,000	95,529,000	99,612,000	98,390,000	119,405,000	100,695,000	86,905,000	89,018,000	115,932,000	100,779,000	110,927,000	88,761,000	93,321,000	57,406,000	32,853,000	56,797,000	58,707,000	45,727,000	40,813,000	39,613,000	35,654,000
Operating Expenses	-10.2%	170,970,000	190,324,000	162,970,000	150,378,000	142,501,000	140,691,000	150,022,000	130,753,000	131,762,000	116,658,000	121,255,000	98,977,000	502,904,000	122,661,000	72,273,000	76,681,000	66,787,000	54,823,000	51,175,000	42,648,000	-
S&GA Expenses	4.5%	86,125,000	82,415,000	91,510,000	83,280,000	78,887,000	73,401,000	79,337,000	66,675,000	69,877,000	62,076,000	68,703,000	56,904,000	55,974,000	51,549,000	44,416,000	50,387,000	38,756,000	32,614,000	32,571,000	26,893,000	-
EBITDA Margin	-9.4%	-0.34	-0.31	-0.24	-0.27	-0.26	-0.27	-0.23	-0.12	-0.06	-0.93	-1.17	-1.53	-1.74	-0.45	-0.25	-0.14	-0.08	-0.41	-0.50	-0.62	-0.73
Interest Expenses	700.0%	8,000	1,000	5,000	19,000	125,000	114,000	109,000	128,000	217,000	219,000	209,000	221,000	317,000	397,000	306,000	662,000	992,000	708,000	695,000	684,000	-
Income Taxes	89.5%	2,354,000	1,242,000	1,647,000	1,093,000	804,000	1,879,000	627,000	719,000	2,456,000	523,000	1,094,000	435,000	6,949,000	585,000	422,000	300,000	108,000	8,000	68,000	34,000	-
Earnings Before Taxes	49.2%	-46,598,000	-91,744,000	-60,767,000	-49,654,000	-16,411,000	-40,035,000	-63,831,000	-41,694,000	-15,993,000	-16,648,000	-9,958,000	-11,116,000	-408,623,000	-65,263,000	-39,745,000	-20,845,000	-7,026,000	-9,595,000	-10,810,000	-3,602,000	-
EBT Margin	-8.7%	-0.40	-0.37	-0.29	-0.32	-0.31	-0.32	-0.28	-0.17	-0.11	-0.97	-1.22	-1.58	-1.79	-0.51	-0.31	-0.18	-0.13	-0.45	-0.54	-0.65	-0.77
Net Income	47.4%	-48,952,000	-92,986,000	-62,414,000	-50,747,000	-17,215,000	-41,914,000	-64,458,000	-42,413,000	-18,449,000	-17,171,000	-11,052,000	-11,551,000	-415,573,000	-65,848,000	-40,167,000	-21,143,000	-7,134,000	-9,603,000	-10,878,000	-3,636,000	-75,524,000
Net Income Margin	-9.1%	-0.41	-0.38	-0.30	-0.33	-0.32	-0.33	-0.29	-0.18	-0.12	-0.99	-1.24	-1.60	-1.82	-0.51	-0.31	-0.18	-0.13	-0.45	-0.54	-0.58	-0.77
Free Cashflow	155.0%	22,308,000	-40,540,000	-36,882,000	-8,684,000	-26,011,000	-46,136,000	-44,182,000	-48,938,000	-21,813,000	-46,443,000	-11,448,000	-42,947,000	-151,514,000	-56,138,000	-36,257,000	-10,655,000	144,000	848,000	-9,058,000	-49,000	-53,403,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Assets	1.8%	965	949	990	1,014	1,029	996	1,002	1,003	1,019	991	978	954	929	1,043	583	610	46.00	573	124
Current Assets	6.0%	596	562	583	602	635	629	666	697	748	744	757	746	774	900	452	430	481	474	106
Cash Equivalents	14.2%	359	315	331	340	227	242	282	320	596	609	649	644	689	834	404	432	476	477	70.00
Inventory	-8.9%	74.00	81.00	84.00	82.00	82.00	79.00	71.00	64.00	60.00	51.00	44.00	39.00	30.00	25.00	22.00	19.00	15.00	13.00	9.00
Net PPE	-1.9%	280	285	285	292	289	258	223	190	169	143	122	107	73.00	65.00	56.00	52.00	49.00	47.00	11.00
Goodwill	0%	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	-	-	-	-	-	-
Liabilities	10.2%	224	203	196	212	223	220	218	197	201	190	193	202	190	217	192	201	78.00	151	101
Current Liabilities	21.4%	127	105	98.00	112	131	127	118	94.00	110	100	113	121	118	146	122	59.00	63.00	48.00	32.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	20.00	22.00	25.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.00	7.00	4.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	20.00	22.00	25.00
Shareholder's Equity	-0.6%	741	745	793	802	806	776	784	807	818	800	785	752	739	825	391	409	420	421	-
Retained Earnings	-4.0%	-1,284	-1,235	-1,142	-1,080	-1,029	-1,012	-970	-905	-863	-844	-827	-816	-805	-389	-323	-283	-262	-255	-231
Additional Paid-In Capital	2.2%	2,026	1,981	1,937	1,884	1,839	1,793	1,758	1,715	1,681	1,645	1,612	1,569	1,544	1,215	715	693	682	677	11.00
Accumulated Depreciation	10.2%	103	94.00	86.00	-	69.00	-	-	-	49.00	44.00	39.00	35.00	31.00	-	-	-	19.00	-	14.00
Shares Outstanding	1.2%	119	118	116	116	115	114	113	113	110	111	109	109	101	101	98.00	97.00	39.00	29.00	13.00
Float	-	-	-	5,700	-	-	-	4,500	-	-	-	18,700	-	-	-	7,300	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	201.8%	25,758	-25,304	-11,526	-4,125	13,723	-9,564	-16,963	-20,802	5,805	-26,216	3,120	-4,082	-130,175	-55,629	-29,518	-2,576	6,700	14,526	4,083	9,318	-
Share Based Compensation	-3.3%	38,918	40,235	45,696	42,101	40,974	33,514	36,313	26,047	26,904	25,950	26,932	16,176	14,269	13,784	13,855	6,718	5,075	3,874	3,025	1,359	-
Cashflow From Investing	167.3%	13,098	4,900	-4,462	119,956	-33,172	-32,630	-27,527	-257,558	-27,618	-20,227	-14,568	-44,316	-22,266	-1,310	-6,739	-8,079	-6,581	-13,678	-13,141	-9,367	-
Cashflow From Financing	28.3%	5,613	4,374	7,096	-3,414	5,001	2,039	6,360	2,417	8,903	6,683	16,193	3,518	7,706	486,968	8,051	-33,819	-1,107	415,638	-864	923	-

TXG Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue	$ 618,727	$ 516,409	$ 490,490
Cost of revenue	209,414	120,386	74,091
Gross profit	409,313	396,023	416,399
Operating expenses:
Research and development	270,332	265,667	211,752
In-process research and development	60,980	0	0
Selling, general and administrative	343,330	298,300	257,560
Accrued contingent liabilities	0	0	(660)
Total operating expenses	674,642	563,967	468,652
Loss from operations	(265,329)	(167,944)	(52,253)
Other income (expense):
Interest income	16,906	6,647	206
Interest expense	(33)	(476)	(866)
Other expense, net	(307)	(198)	(802)
Total other income (expense)	16,566	5,973	(1,462)
Loss before provision for income taxes	(248,763)	(161,971)	(53,715)
Provision for income taxes	6,336	4,029	4,508
Net loss	$ (255,099)	$ (166,000)	$ (58,223)
Net loss per share, basic (in dollars per share)	$ (2.18)	$ (1.46)	$ (0.53)
Net loss per share, diluted (in dollars per share)	$ (2.18)	$ (1.46)	$ (0.53)
Weighted-average shares used to compute net loss per share, basic (in shares)	117,165,036	113,858,684	110,347,937
Weighted-average shares used to compute net loss per share, diluted (in shares)	117,165,036	113,858,684	110,347,937

TXG Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 359,284	$ 219,746
Marketable securities	29,411	210,238
Restricted cash	0	2,633
Accounts receivable, net	114,832	104,211
Inventory	73,706	81,629
Prepaid expenses and other current assets	18,789	16,578
Total current assets	596,022	635,035
Property and equipment, net	279,571	289,328
Restricted cash	0	4,974
Operating lease right-of-use assets	65,361	69,882
Goodwill	4,511	4,511
Intangible assets, net	16,616	22,858
Other noncurrent assets	3,062	2,392
Total assets	965,143	1,028,980
Current liabilities:
Accounts payable	15,738	21,599
Accrued compensation and related benefits	30,105	32,675
Accrued expenses and other current liabilities	56,648	59,779
Deferred revenue	13,150	7,867
Operating lease liabilities	11,521	9,037
Total current liabilities	127,162	130,957
Operating lease liabilities, noncurrent	83,849	86,139
Deferred revenue, noncurrent	8,814	3,165
Other noncurrent liabilities	4,275	2,976
Total liabilities	224,100	223,237
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock, $0.00001 par value; 100,000,000 shares authorized, no shares issued or outstanding as of December 31, 2023 and 2022	0	0
Common stock, $0.00001 par value; 1,100,000,000 shares authorized (Class A 1,000,000,000, Class B 100,000,000); 119,095,362 (Class A 105,038,529, Class B 14,056,833) and 115,195,009 (Class A 96,527,754, Class B 18,667,255) shares issued and outstanding as of December 31, 2023 and 2022, respectively	2	2
Additional paid-in capital	2,025,890	1,839,397
Accumulated deficit	(1,284,420)	(1,029,321)
Accumulated other comprehensive loss	(429)	(4,335)
Total stockholders’ equity	741,043	805,743
Total liabilities and stockholders’ equity	$ 965,143	$ 1,028,980

About 10X Genomics Inc

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

CEO	Dr. Serge Saxonov Ph.D.
WEBSITE	10xgenomics.com
INDUSTRY	Healthcare Plans
EMPLOYEES	1243

10X Genomics Inc Frequently Asked Questions

What is the ticker symbol for 10X Genomics Inc? What does TXG stand for in stocks?

TXG is the stock ticker symbol of 10X Genomics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of 10X Genomics Inc (TXG)?

As of Thu Apr 25 2024, market cap of 10X Genomics Inc is 3.2 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TXG stock?

You can check TXG's fair value in chart for subscribers.

What is the fair value of TXG stock?

You can check TXG's fair value in chart for subscribers. The fair value of 10X Genomics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of 10X Genomics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TXG so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is 10X Genomics Inc a good stock to buy?

The fair value guage provides a quick view whether TXG is over valued or under valued. Whether 10X Genomics Inc is cheap or expensive depends on the assumptions which impact 10X Genomics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TXG.

What is 10X Genomics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, TXG's PE ratio (Price to Earnings) is -12.55 and Price to Sales (PS) ratio is 5.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TXG PE ratio will change depending on the future growth rate expectations of investors.